GT Biopharma Inc (GTBP)

GT Biopharma's stock price has declined significantly, dropping by 70.31% in the past six months and 71.67% from January 13, 2025, to January 9, 2026. Recent events include news commentary on immunotherapies replacing chemotherapy, a $3.2 million registered direct offering, the Third Quarter 2025 Financial Results, participation in the Centurion One Capital 3rd Annual Bahamas Summit, and updates on the GTB-3650 Phase 1 Trial. The 10-day moving average crossed bullishly above the 50-day moving average on December 22, 2025, and GTBP moved above its 50-day moving average on January 12, 2026.

Information directly detailing demand seasonality for GT Biopharma, Inc.'s products and services is not explicitly available. Historical data on mean and median monthly returns for GTBP can be used to identify seasonal patterns, suggesting that such patterns might exist for the stock. Demand for its product candidates is primarily driven by clinical trial progress, regulatory approvals, and market adoption, rather than typical consumer seasonality.

GT Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing immuno-oncology therapies, operating in the Healthcare sector, specifically in Biotechnology and Pharmaceuticals. Its core technology is the TriKE™ NK cell engager platform, designed to enhance the cancer-killing abilities of natural killer cells. Key product candidates include GTB-3550 for AML and MDS, GTB-3650 targeting CD33 on myeloid leukemias, GTB-5550 targeting B7-H3 on solid tumors, and GTB-7550 for lupus and autoimmune disorders. GT Biopharma has a worldwide license agreement with the University of Minnesota for its TriKE™ technology.

GT Biopharma, Inc. is headquartered in San Francisco, California, United States, focusing on developing and commercializing novel immuno-oncology products in the United States. The company's license agreement with the University of Minnesota for TriKE™ technology is a worldwide agreement.

GT Biopharma's reputation has been influenced by advancements in clinical trials and its position in the immuno-oncology market. News highlights the potential of immunotherapies, with the blood cancer market projected to reach $13 billion by 2030, and the role of natural killer cell therapies. The company has also received "Buy" recommendations from analysts at Roth MKM, contributing positively to its scientific and market perception.

The ownership structure of GT Biopharma stock includes institutional investors (1.53% to 8.15%), insiders (8.05%), and retail investors (approximately 90.11%). Major institutional owners include DRW Securities, LLC, Bank Of Montreal, Citadel Advisors Llc, Geode Capital Management, Llc, Two Sigma Securities, Llc, Morgan Stanley, FSMAX - Fidelity Extended Market Index Fund, VEXMX - Vanguard Extended Market Index Fund Investor Shares, Vanguard Group Inc, and Wells Fargo & Company/mn. Michael Martin Breen owns the most shares among individual investors.